0.78%
-5.14%
-8.46%
-18.91%
-3.07%
61.16%
-0.53%
AI Spotlight on SRPT
Company Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program.
It has collaboration agreements with F.Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio.The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Market Data
| Last Price | 115.34 |
| Change Percentage | 0.78% |
| Open | 114.87 |
| Previous Close | 114.45 |
| Market Cap ( Millions) | 11017 |
| Volume | 29665 |
| Year High | 173.25 |
| Year Low | 102.16 |
| M A 50 | 120.93 |
| M A 200 | 129.05 |
Financial Ratios
| FCF Yield | -4.27% |
| Dividend Yield | 0.00% |
| ROE | 11.83% |
| Debt / Equity | 114.45% |
| Net Debt / EBIDTA | 666.86% |
| Price To Book | 9.01 |
| Price Earnings Ratio | 90.3 |
| Price To FCF | -23.42 |
| Price To sales | 6.72 |
| EV / EBITDA | 67.91 |
News
- Jan -27 - Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS
- Jan -16 - Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely
- Jan -13 - Sarepta's Elevidys launch remains strong with solid beat, says JPMorgan
- Jan -13 - Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue
- Jan -07 - Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
- Jan -06 - SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell?
- Jan -06 - Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Dec -31 - Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dec -20 - Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku
- Dec -19 - 4 Biotech Stocks Most Wall Street Analysts Are Bullish About
- Dec -19 - SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder
- Dec -18 - Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
- Dec -17 - 3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
- Dec -13 - FDA's new accelerated approval guidance to benefit rare disease drug development, analysts believe
- Dec -13 - Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?
- Nov -29 - Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Nov -29 - Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?
- Nov -27 - SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies
- Nov -27 - Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 42.11%: Read This Before Placing a Bet
- Nov -26 - Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> RNA-targeted Therapeutics, Gene Therapy and Other Genetic Therapeutic Modalities
Expected Growth : 13.93 %
What the company do ?
Sarepta Therapeutics, Inc. develops RNA-targeted therapeutics, gene therapy, and genetic therapeutic modalities to treat rare genetic diseases, focusing on Duchenne muscular dystrophy and other neuromuscular disorders.
Why we expect these perspectives ?
Sarepta Therapeutics' RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities are driven by increasing demand for rare disease treatments, advancements in gene editing technologies, and a strong pipeline of novel therapies. The company's focus on Duchenne muscular dystrophy and other neuromuscular diseases, as well as its strategic partnerships, contribute to its 13.93% growth.
Sarepta Therapeutics, Inc. Products
| Product Range | What is it ? |
|---|---|
| EXONDYS 51 | EXONDYS 51 is a disease-modifying therapy for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. |
| VYONDYS 53 | VYONDYS 53 is a disease-modifying therapy for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. |
| AMONDYS 45 | AMONDYS 45 is a disease-modifying therapy for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping. |
Sarepta Therapeutics, Inc.'s Porter Forces
Threat Of Substitutes
Sarepta Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments for muscular dystrophy and other rare genetic diseases.
Bargaining Power Of Customers
Patients and healthcare providers have limited bargaining power due to the rarity of the diseases treated by Sarepta Therapeutics, Inc. and the lack of alternative treatments.
Bargaining Power Of Suppliers
Sarepta Therapeutics, Inc. relies on a few key suppliers for raw materials and manufacturing services, giving them some bargaining power.
Threat Of New Entrants
The biotechnology industry is highly competitive, and new entrants can easily disrupt the market with innovative treatments and therapies.
Intensity Of Rivalry
The biotechnology industry is highly competitive, with many established players and new entrants vying for market share and patent protection.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 59.37% |
| Debt Cost | 3.95% |
| Equity Weight | 40.63% |
| Equity Cost | 8.64% |
| WACC | 5.85% |
| Leverage | 146.14% |
Sarepta Therapeutics, Inc. : Quality Control
Sarepta Therapeutics, Inc. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, … |
| BPMC | Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment … |
| RNA | Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The … |
| AGIO | Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) … |
| SWTX | SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Agios Pharmaceuticals
A-Score
1-Year Total Return ->
🥈
Avidity Biosciences
A-Score
1-Year Total Return ->
🥉
Crinetics Pharmaceuticals
A-Score
1-Year Total Return ->
4
Blueprint Medicines
A-Score
1-Year Total Return ->
5
Sarepta Therapeutics
A-Score
1-Year Total Return ->
6
